Clostridium difficile

Size: px
Start display at page:

Download "Clostridium difficile"

Transcription

1 Clostridium difficile Alex Aspinall MD, PhD, FRCPC Clinical Assistant Professor, University of Calgary Division of Gastroenterology and Hepatology, South Health Campus 1

2 Learning Points C. difficile is the leading cause of antibiotic associated diarrhea Fecal-oral transmission (spores) Disruption of the normal intestinal flora (antimicrobials) allows colonization Production of exotoxins that bind to intestinal epithelium Inflammation Diarrhea 2

3 Learning Points Patients can: Be asymptomatic carriers Have infection with colitis (CDAC) Have fulminant colitis/ileus/toxic megacolon Therapy Stop predisposing antibiotics ASAP Mild Disease: Metronidazole 500mg po tid Severe Disease: Vancomycin 125mg po qid ( to 500mg qid if no response) Infection Control Wash hands with soap and water Spores are alcohol resistant 3

4 Introduction Therapy of Recurrence: First: same therapy as before Second: tapering course of Vancomycin Consider Fidaxomicin 200 mg po bid for 10 days Subsequent: Fecal transplant Vancomycin 125 mg po qid for 7-14 days 125 mg po tid for 7 days 125 mg po od for 7 days 125 mg po eod for 7 days 125 mg po q3 days for 14 days 4

5 Epidemiology USA, 2011 ~453,000 cases 83,000 first recurrences 29,300 patients died Risk Factors Women>Men White>non-White Age ,700 Community Acquired 293,000 Healthcare Associated Lessa FC et al. N Engl J Med 2015;372:

6 Adjusted U.S. National Estimates of Burden and Incidence of CDI, Lessa FC et al. N Engl J Med 2015;372:

7 Adjusted U.S. National Estimates of Recurrences and Deaths Associated with CDI, According to Epidemiologic Category, Lessa FC et al. N Engl J Med 2015;372:

8 Epidemiology J strain highly resistant to clindamycin Implicated in large outbreaks of diarrhea in four hospitals in the United States New strain BI, NAP1, or ribotype 027 More frequent, severe, refractory to standard therapy, and likely to relapse than previously described Increased endotoxin production Fluoroquinolone use has strongly correlated with the emergence Johnson et al. N Engl J Med 1999; 341:1645 Bartlett, Ann Intern Med 2006; 145:758 He et al, Nat Genet 2013; 45:

9 Transmission Patients who carry C. difficile reservoir for environmental contamination presence or absence of clinical infection C difficile is highly transmissible Fecal oral route by ingestion of spores Dramatic increases in the incidence and severity of healthcare associated C. difficile infection have occurred since 2000, particularly in patients over age 65 Readily cultured from the hospital environment Items in patient rooms Hands, clothing, stethoscopes of healthcare workers Infection is also transmitted readily between hospital roommates Receipt of antibiotics by prior bed occupants associated with increased risk for C. difficile infection in subsequent patients 9

10 Nosocomial Infections C. difficile carriers 20-50% of adults in hospitals and longterm care facilities carrier rate among healthy adults is about 3% ~20% of patients with negative admission stool cultures become infected during hospitalization Although asymptomatic, these individuals are capable of shedding spores of C. difficile serve as a reservoir for environmental contamination to other hospitalized patients New exposure and colonization more likely to lead to CDAD Patients previously colonized more likely to remain asymptomatic during their hospitalization McFarland et al. N Engl J Med 1989; 320:204 Zacharioudakis et al, Am J Gastroenterol 2015; 110:381 Riggs et al, Clin Infect Dis 2007; 45:

11 Community-Acquired Infections On the rise Minnesota county ( ) incidence of both communityacquired and hospital-acquired infection increased dramatically 385 cases, 41 percent were community acquired Patients with community-acquired younger (median age 50 versus 72) Healthier female > male (76 vs 60%) Less likely to have antibiotic exposure (78 vs 94%) acid suppressants (22 vs 47%) to have cancer (17 vs 32%) to have severe infection (20 vs 31%) Risk for recurrence did not differ between the two groups (28 vs 30%) 11

12 Risk Factors Antibiotic use most widely recognized modifiable risk factor for CDAD Other RF Hospitalization advanced age severe illness gastric acid suppression enteral feeding gastrointestinal surgery Obesity cancer chemotherapy hematopoietic stem cell transplantation For recurrent C. difficile infection include age 75 years 10 unformed stools per 24 hour period, serum creatinine 1.2 mg/dl For Complications perforation, toxic megacolon, colectomy, admission to intensive care unit, death Older age ( 80 years) abnormal blood tests white blood cell count <4 or 20 albumin <25 g/l blood urea nitrogen >7 mmol/l CRP 150 mg/l abnormal vital signs heart rate >90/minute, respiratory rate >20/minute 12

13 Antibiotics and CDAC Frequently associated Occasionally associated Rarely associated Fluoroquinolones Macrolides Aminoglycosides Clindamycin Cephalosporins (broad spectrum) Penicillins Trimethoprimsulfamethoxazole Tetracyclines Metronidazole Vancomycin 13

14 Pathophysiology C. difficile diarrhea genes for toxin A (tcda) and toxin B (tcdb) inactivate members of the Rho family of guanosine triphosphatases (Rho GTPases) leading to colonocyte death, loss of intestinal barrier function, and neutrophilic colitis Serum antitoxin antibodies are the best described host factor protecting against C. difficile pathogenesis Recurrent CDI recurrence following initial infection not fully understood persistent spores from the initial infection C. difficile spores in colonic diverticula may escape mechanical clearance by peristalsis Antibiotic resistance does not appear to be a factor in recurrence 14

15 Clinical Manifestations Watery diarrhea is the cardinal symptom of C. difficile associated diarrhea 3 loose stools in 24 hours Lower abdominal pain and cramping Low grade fever, nausea, anorexia, and leukocytosis Diarrhea may be associated with mucus or occult blood Melena or hematochezia are rare Fever in 15% of cases Temperature >38.5 C is a sign of severe CDAD. Leukocytosis, elevated creatinine, and elevated lactate in the setting of CDAD are common; CDAD is routinely associated with an average white blood cell count of 15,000/microL 15

16 Symptoms Symptoms of CDI antibiotic therapy During antibiotic therapy 5 to 10 days following antibiotic therapy Rarely, 10 weeks after cessation of antibiotic Unexplained leukocytosis in hospitalized patients even in the absence of diarrhea positive stool C. difficile toxin was observed in 58% of cases (vs 12% in controls) When unexplained leukocytosis is due to CDI, diarrhea typically develops one to two days later. 16

17 Clinical Manifestations Type of infection Diarrhea Other symptoms Diarrhea with colitis Fulminant colitis Asymptomatic carriage Multiple loose bowel movements per day Occult bleeding may be seen Hematochezia rare Diarrhea may be severe OR diminished (due to paralytic ileus and colonic dilatation) Surgical consult required; colectomy can be life saving Nausea, anorexia, fever, malaise, dehydration, leukocytosis with left shift Lethargy, fever, tachycardia, abdominal pain; dilated colon/paralytic ileus may be demonstrated on plain abdominal film Physical examination Abdominal distention, tenderness May present as acute abdomen; peritoneal signs suggest perforation Absent Absent Normal Normal Sigmoidoscopic examination Diffuse or patchy nonspecific colitis Sigmoidoscopy and colonoscopy contraindicated; flexible proctoscopy with minimal air insufflation may be diagnostic 17

18 Fulminant Colitis Clinical manifestations diarrhea lower quadrant/diffuse abdominal pain abdominal distention fever hypovolemia lactic acidosis hypoalbuminemia elevated creatinine marked leukocytosis ( 40,000 white blood cells/µl) 18

19 Recurrent Disease Recurrent C. difficile complete abatement of CDI symptoms while on appropriate therapy subsequent reappearance of symptoms after treatment has been stopped 25 percent of patients experience recurrent C. difficile within 30 days of treatment Less commonly, recurrent CDI can occur as late as two to three months after discontinuation of treatment Once patients have experienced one recurrence, they are at significantly increased risk for further recurrences 19

20 Unusual Presentations Protein losing enteropathy Hypoalbuminemia in the absence of fulminant colitis Inflammation of the bowel leakage of albumin into the lumenserum albumin levels may drop below 20 g/l Ascites and peripheral edema may be observed The protein losing enteropathy responds to appropriate medical therapy of the infection Extracolonic involvement Appendicitis Small bowel involvement - older adults and/or patients with multiple comorbidities prior colectomy with ileostomy manifestations may include increased ileostomy output pseudomembranes Increased risk for fulminant disease with a high mortality rate Rare cases of cellulitis, soft tissue infection, bacteremia, and reactive arthritis 20

21 Diagnosis Clinically significant diarrhea or ileus relevant risk factors (including recent antibiotic use, hospitalization, and advanced age) positive laboratory stool test for C. difficile toxins or C. difficile toxin gene Pseudomembranous colitis highly suggestive of C. difficile infection and should prompt laboratory testing 21

22 Who Should be Tested? Only in patients with clinically significant diarrhea testing cannot distinguish between CDAD and asymptomatic carriers (who do not warrant treatment). For patients with ileus, laboratory diagnosis via perirectal swab for toxin assay or anaerobic culture may be performed 22

23 A Word on When to Test There is no role for repeat laboratory testing or testing for cure There is no role for laboratory testing in asymptomatic patients There is no role for repeat testing in patients receiving treatment for acute C. difficile infection Repeat stool assays are NOT warranted during or following treatment in patients who are recovering or are symptom free 50%of patients have positive stool assays for as long as six weeks after the completion of therapy Stool assays may remain positive during or after clinical recovery 23

24 Endoscopy Lower gastrointestinal endoscopy is not warranted in patients with classic clinical manifestations of C. difficile infection, a positive laboratory test, and/or clinical response to empiric treatment circumstances in which an alternative diagnosis is suspected that requires direct visualization and/or biopsy of the bowel mucosa. It may also be helpful for patients with ileus or fulminant colitis in the absence of diarrhea since it may allow visualization of pseudomembranes not all patients with CDAD have pseudomembranes, particularly patients with mild or partially treated infection 24

25 Differential Diagnoses C. difficile must be distinguished from other infectious and noninfectious causes of diarrhea. Most antibiotic-associated diarrhea is not attributable to C. difficile infection (but rather to osmotic mechanisms), whereas antibiotic-associated diarrhea associated with colitis is nearly always C. difficile associated diarrhea (CDAD) 25

26 Osmotic vs C. difficile Diarrhea 26

27 Other Infectious Diarrhea Staphylococcus aureus Klebsiella oxytoca Clostridium perfringens Possibly Candida albicans Salmonella can present as a pseudomembranous colitis (severe inflammation of the inner lining of the bowel) 27

28 Other Non-infectious Diarrhea Mimics of C. difficile infection: Post-infectious irritable bowel syndrome Inflammatory bowel disease Celiac disease Collagenous colitis. Differentiation of noninfectious antibiotic associated diarrhea from C. difficile infection may be difficult Especially in patients who are asymptomatic C. difficile carriers Most relevant among patients in nursing homes or hospitals where the rate of asymptomatic carriage is 10 to 50 percent in community populations, the rate of asymptomatic carriage is 5 percent Cessation of symptoms with discontinuation of oral intake is a distinguishing feature of osmotic diarrhea 28

29 Post-infectious Irritable Bowel Syndrome Post-infectious irritable bowel syndrome occurs in about 10 percent of patients who have been successfully treated for an initial episode of C. difficile these patients may have up to 10 watery stools per day this must be distinguished from a relapse of the original C. difficile infection 29

30 Association with Inflammatory Bowel Disease Infection with C. difficile may complicate the course of inflammatory bowel disease Enteric infections account for about 10% of symptomatic relapses in patients with IBD C. difficile accounts for about half of these infections 30

31 Treatment Indications for treatment Patients with typical manifestations of C. difficile infection (eg, diarrhea, abdominal pain, or nausea and vomiting) and a positive diagnostic assay should receive antibiotics for treatment for C. difficile infection Empiric therapy is appropriate pending results of diagnostic testing if the clinical suspicion is high Treatment of C. difficile infection is not indicated in patients who have a positive toxin assay but are asymptomatic 31

32 Treatment Stop precipitating antibiotics ASAP Infection Control Use Soap and Water to wash hands C. difficile spores are resistant to alcohol 32

33 Treatment Initial episode Mild disease: metronidazole 500 mg orally three times daily or 250 mg four times daily for 10 to 14 days Severe disease: vancomycin 125 mg orally four times daily for 10 to 14 days First relapse Confirm diagnosis If symptoms are mild, conservative management may be appropriate If antibiotics are needed, repeat treatment as in initial episode above. Alternative: fidaxomicin 200 mg orally twice daily for 10 days. 33

34 Treatment Second relapse Confirm diagnosis Tapering and pulsed oral vancomycin (below), with or without probiotics (for example, Saccharomyces boulardii 500 mg orally twice daily). The probiotics may be overlapped with the final week of the taper and continued for two additional weeks in the absence of antibiotics. 125 mg orally four times daily for 7 to 14 days 125 mg orally twice daily for 7 days 125 mg orally once daily for 7 days 125 mg orally every other day for 7 days 125 mg orally every 3 days for 14 days Alternative: fidaxomicin 200 mg orally twice daily for 10 days 34

35 Treatment Subsequent relapse Confirm diagnosis Fidaxomicin 200 mg orally twice daily for 10 days if not used previously Fecal bacteriotherapy (fecal microbiota transplant) 35

36 Severe Disease Initial Treatment Oral vancomycin (125 mg four times daily) (consider an increase to 500mg four times daily if not improving) If ileus, ADD metronidazole 500 mg iv every eight hours If not improving, consider fidaxomicin 200 mg orally twice daily Consider Surgery Toxic megacolon, Ileus, Peritoneal signs Immunocompetent, age 65 years, WBC 20,000/ µl, plasma lactate meq/l 36

37 What about Probiotics? Probiotics are live, nonpathogenic bacteria capable of colonizing the colonic mucosa The alteration of gut microflora in the setting of CDAD has raised interest in a potential role for use of probiotics to restore a diverse intestinal microflora after disruption by antimicrobial therapy and CDAD Johnston, Ann Intern Med 2012; 157:

38 Probiotics and CDAD Prevention In patients receiving antibiotics who are at increased risk for CDAD, coadministration might decrease the chance of developing CDAD Meta-analysis including 20 randomized trials and 3818 patients, probiotics reduced the incidence of CDAD by 66 percent Relative risk of 0.34 (95% CI ) Large RCT 2941 older adults with antibiotic exposure Probiotics multistrain preparation of Lactobacillus acidophilus and Bifidobacterium bifidum No risk reduction for CDAD (RR 0.71; 95% CI ) Another large RCT 2444 hospitalized patients Stopped early for futility Johnston, Ann Intern Med 2012; 157:878 Allen, Lancet 2013; 382:1249 Erhardt, Open Forum Infect Dis 2016;

39 Probiotics and CDAD Treatment Two meta-analyses Treatment of antibiotic-associated diarrhea Suggested a possible benefit of probiotics for treatment of CDAD Routine use not usually recommended Patients with recurrent disease that is not severe No significant comorbidities Hempel, JAMA 2012; 307:1959 Ritchie, PLoS One 2012;

40 Probiotics Regimens Publication date Probiotic regimen studied Study population Study findings Similar (commercially available) product* Studies in adults Beausoleil et al (2007) L. acidophilus and L. casei (25 x 109 CFU/day for 2 days, then 50 x 109 CFU/day for duration of the antibiotic course) 89 adults (inpatients) Antibiotic associated diarrhea occurred in 16% of treated patients and 36% of patients in placebo group (OR 0.34; 95% CI 0.12 to 0.94; p = 0.05) BioK Hickson et al (2007) L. casei (19 x 109 CFU/day), L. bulgaris (1.9 x 109 CFU/day), and S. thermophiles (19 x 109 CFU/day) within 48 hours of starting antibiotic therapy until 7 days after discontinuation 135 adults (inpatients) Antibiotic associated diarrhea occurred in 12% of treated patients and 34% of patients in placebo group (p = 0.007; arr 0.17 [ ]). Actimel (also known as Danactive in United States and Canada) 40

41 Probiotics and Risks A small number of case reports Bacteremia or fungemia attributed to probiotics Saccharomyces boulardii and Lactobacillus rhamnosus GG Severe comorbidities, immunosuppressive medication, recent surgical intervention, recent prolonged hospitalization 41

42 On the Horizon. 42

43 Decreased Recurrent C. difficile infection 43

44 Learning Points C. difficile is the leading cause of antibiotic associated diarrhea Fecal-oral transmission (spores) Disruption of the normal intestinal flora (antimicrobials) allows colonization Production of exotoxins that bind to intestinal epithelium Inflammation Diarrhea 44

45 Learning Points Patients can: Be asymptomatic carriers Have infection with colitis (CDAC) Have fulminant colitis/ileus/toxic megacolon Therapy Stop predisposing antibiotics ASAP Mild Disease: Metronidazole 500mg po tid Severe Disease: Vancomycin 125mg po qid ( to 500mg qid if no response) Infection Control Wash hands with soap and water Spores are alcohol resistant 45

46 Questions? 46

CLOSTRIDIUM DIFICILE. Negin N Blattman Infectious Diseases Phoenix VA Healthcare System

CLOSTRIDIUM DIFICILE. Negin N Blattman Infectious Diseases Phoenix VA Healthcare System CLOSTRIDIUM DIFICILE Negin N Blattman Infectious Diseases Phoenix VA Healthcare System ANTIBIOTIC ASSOCIATED DIARRHEA 1978: C diff first identified 1989-1992: Four large outbreaks in the US caused by J

More information

ENGLISH FOR PROFESSIONAL PURPOSES UNIT 3 HOW TO DEAL WITH CLOSTRIDIUM DIFFICILE

ENGLISH FOR PROFESSIONAL PURPOSES UNIT 3 HOW TO DEAL WITH CLOSTRIDIUM DIFFICILE ENGLISH FOR PROFESSIONAL PURPOSES UNIT 3 HOW TO DEAL WITH CLOSTRIDIUM DIFFICILE The diagnosis of CDI should be based on a combination of clinical and laboratory findings. A case definition for the usual

More information

Clostridium Difficile Infection in Adults Treatment and Prevention

Clostridium Difficile Infection in Adults Treatment and Prevention Clostridium Difficile Infection in Adults Treatment and Prevention Definition: Clostridium Difficile colonizes the human intestinal tract after the normal gut flora has been altered by antibiotic therapy

More information

9/18/2018. Clostridium Difficile: Updates on Diagnosis and Treatment. Clostridium difficile Infection (CDI) Clostridium difficile Infection (CDI)

9/18/2018. Clostridium Difficile: Updates on Diagnosis and Treatment. Clostridium difficile Infection (CDI) Clostridium difficile Infection (CDI) Clostridium Difficile: Updates on Diagnosis and Treatment Elizabeth Hudson, DO, MPH 9/25/18 Antibiotic-associated diarrhea and colitis were well established soon after widespread use of antibiotics In

More information

Division of GIM Lecture Series Case Presentation David A. Erickson, M.D October 9th, 2013

Division of GIM Lecture Series Case Presentation David A. Erickson, M.D October 9th, 2013 Division of GIM Lecture Series Case Presentation David A. Erickson, M.D October 9th, 2013 Financial Disclosures No financial disclosures Objectives Review a case of recurrent Clostridium difficile infection

More information

Diagnosis, Management, and Prevention of Clostridium difficile infection in Long-Term Care Facilities: A Review

Diagnosis, Management, and Prevention of Clostridium difficile infection in Long-Term Care Facilities: A Review Diagnosis, Management, and Prevention of Clostridium difficile infection in Long-Term Care Facilities: A Review October 18, 2010 James Kahn and Carolyn Kenney, MSIV Overview Burden of disease associated

More information

Stony Brook Adult Clostridium difficile Management Guidelines. Discontinue all unnecessary antibiotics

Stony Brook Adult Clostridium difficile Management Guidelines. Discontinue all unnecessary antibiotics Stony Brook Adult Clostridium difficile Management Guidelines Summary: Use of the C Diff Infection (CDI) PowerPlan (Adult) Required Patient with clinical findings suggestive of Clostridium difficile infection

More information

Clostridium difficile Infection: Diagnosis and Management

Clostridium difficile Infection: Diagnosis and Management Clostridium difficile Infection: Diagnosis and Management Brian Viviano D.O. Case study 42 year old female with history of essential hypertension and COPD presents to ED complaining of 24 hours of intractable,

More information

Probiotics for Primary Prevention of Clostridium difficile Infection

Probiotics for Primary Prevention of Clostridium difficile Infection Probiotics for Primary Prevention of Clostridium difficile Infection Objectives Review risk factors for Clostridium difficile infection (CDI) Describe guideline recommendations for CDI prevention Discuss

More information

Clostridium difficile CRISTINA BAKER, MD, MPH INFECTIOUS DISEASE PARK NICOLLET/HEALTH PARTNERS 11/9/2018

Clostridium difficile CRISTINA BAKER, MD, MPH INFECTIOUS DISEASE PARK NICOLLET/HEALTH PARTNERS 11/9/2018 Clostridium difficile CRISTINA BAKER, MD, MPH INFECTIOUS DISEASE PARK NICOLLET/HEALTH PARTNERS 11/9/2018 Disclosures None Objectives Highlight important changes in the management of Clostridium difficile

More information

ABSTRACT PURPOSE METHODS

ABSTRACT PURPOSE METHODS ABSTRACT PURPOSE The purpose of this study was to characterize the CDI population at this institution according to known risk factors and to examine the effect of appropriate evidence-based treatment selection

More information

Clostridium difficile Infection (CDI) Management Guideline

Clostridium difficile Infection (CDI) Management Guideline Clostridium difficile Infection (CDI) Management Guideline Do not test all patients with loose or watery stools for CDI o CDI is responsible for

More information

Updated Clostridium difficile Treatment Guidelines

Updated Clostridium difficile Treatment Guidelines Updated Clostridium difficile Treatment Guidelines Arielle Arnold, PharmD, BCPS Clinical Pharmacist Saint Alphonsus Regional Medical Center September 29 th, 2018 Disclosures Nothing to disclose Learning

More information

Case 1. Which of the following would be next appropriate investigation/s regarding the pts diarrhoea?

Case 1. Which of the following would be next appropriate investigation/s regarding the pts diarrhoea? Case 1 21 yr old HIV +ve, Cd4-100 HAART naïve Profuse diarrhoea for 3/52. Stool MC&S ve Which of the following would be next appropriate investigation/s regarding the pts diarrhoea? Repeat stool MC&S Stool

More information

The Epidemiology of Clostridium difficile DANIEL SAMAN, DRPH, MPH RESEARCH SCIENTIST ESSENTIA INSTITUTE OF RURAL HEALTH

The Epidemiology of Clostridium difficile DANIEL SAMAN, DRPH, MPH RESEARCH SCIENTIST ESSENTIA INSTITUTE OF RURAL HEALTH The Epidemiology of Clostridium difficile DANIEL SAMAN, DRPH, MPH RESEARCH SCIENTIST ESSENTIA INSTITUTE OF RURAL HEALTH Some history first Clostridium difficile, a spore-forming gram-positive (i.e., thick

More information

EDUCATIONAL COMMENTARY CLOSTRIDIUM DIFFICILE UPDATE

EDUCATIONAL COMMENTARY CLOSTRIDIUM DIFFICILE UPDATE EDUCATIONAL COMMENTARY CLOSTRIDIUM DIFFICILE UPDATE Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE credits click

More information

Clostridium Difficile Associated Disease. Edmund Krasinski, Jr., D.O., F.A.C.G. Southwest Conference on Medicine 2011

Clostridium Difficile Associated Disease. Edmund Krasinski, Jr., D.O., F.A.C.G. Southwest Conference on Medicine 2011 Clostridium Difficile Associated Disease Edmund Krasinski, Jr., D.O., F.A.C.G. Southwest Conference on Medicine 2011 Introduction Which of the following is more common in community hospitals in the Southeast

More information

ACG Clinical Guideline: Diagnosis, Treatment, and Prevention of Clostridium difficile Infections

ACG Clinical Guideline: Diagnosis, Treatment, and Prevention of Clostridium difficile Infections ACG Clinical Guideline: Diagnosis, Treatment, and Prevention of Clostridium difficile Infections Christina M. Surawicz, MD 1, Lawrence J. Brandt, MD 2, David G. Binion, MD 3, Ashwin N. Ananthakrishnan,

More information

Management of the Hospitalized IBD Patient. Drew DuPont MD

Management of the Hospitalized IBD Patient. Drew DuPont MD Management of the Hospitalized IBD Patient Drew DuPont MD Ulcerative Colitis: Indications for Admission Severe ulcerative colitis Frequent loose bloody stools ( 6 per day) Severe cramps Systemic toxicity:

More information

DISCLOSURE Relevant relationships with commercial entities Wyeth (received advisory board & speaker honoraria) Potential for conflicts of interest wit

DISCLOSURE Relevant relationships with commercial entities Wyeth (received advisory board & speaker honoraria) Potential for conflicts of interest wit GASTROENTERITIS DISCLOSURE Relevant relationships with commercial entities Wyeth (received advisory board & speaker honoraria) Potential for conflicts of interest within this presentation fidaxomicin (which

More information

Clostridium difficile

Clostridium difficile Clostridium difficile Care Homes IPC Study Day Sue Barber Infection Prevention & Control Lead AV & Chiltern CCG s Clostridium difficile A spore forming Bacterium. Difficult to grow in the laboratory hence

More information

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics. DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this

More information

Bezlotoxumab (Zinplava) as Adjunct Treatment for Clostridium difficile. Janel Liane Cala, RPh Medical Center Hospital

Bezlotoxumab (Zinplava) as Adjunct Treatment for Clostridium difficile. Janel Liane Cala, RPh Medical Center Hospital Bezlotoxumab (Zinplava) as Adjunct Treatment for Clostridium difficile Janel Liane Cala, RPh Medical Center Hospital Objectives Review pathophysiology, risk factors, prevention, and treatment options of

More information

Clostridium difficile: Can you smell the new updates?

Clostridium difficile: Can you smell the new updates? Clostridium difficile: Can you smell the new updates? Sunish Shah, Pharm.D. PGY-2 Infectious Disease Pharmacy Resident Yale-New Haven Hospital sshah1741@mail.usciences.edu Learning objectives Recognize

More information

Update on Clostridium difficile infection.

Update on Clostridium difficile infection. Update on Clostridium difficile infection. K. Honein Gastroenterologist, HDF Associate Professor Head of Medicine Department St Joseph University-Beirut. Introduction Gram+anaerobic bacillus responsible

More information

! MQ is a 44 year old woman that I first saw in Sept ! In MVA in Jan 2003 requiring spinal surgery

! MQ is a 44 year old woman that I first saw in Sept ! In MVA in Jan 2003 requiring spinal surgery Case MQ is a 44 year old woman that I first saw in Sept 2006 UPDATE ON CLOSTRIDIUM DIFFICILE DISEASE Richard A. Jacobs, M.D.,PhD In MVA in Jan 2003 requiring spinal surgery Subsequently developed fecal

More information

Incidence of and risk factors for communityassociated Clostridium difficile infection

Incidence of and risk factors for communityassociated Clostridium difficile infection University of Iowa Iowa Research Online Theses and Dissertations 2010 Incidence of and risk factors for communityassociated Clostridium difficile infection Jennifer Lee Kuntz University of Iowa Copyright

More information

Clostridium DifficileInfection & Readmissions: An ounce of prevention is worth a pound of cure

Clostridium DifficileInfection & Readmissions: An ounce of prevention is worth a pound of cure Clostridium DifficileInfection & Readmissions: An ounce of prevention is worth a pound of cure Brian S. Zuckerbraun, MD, FACS Henry T. Bahnson Professor of Surgery University of Pittsburgh Chief, Trauma

More information

Clostridium difficile Essential information

Clostridium difficile Essential information Clostridium difficile Essential information Clostridium difficile Origins Clostridium difficile (C. diff) is a Gram positive, spore forming, anaerobic bacterium with a rod structure. It was first identified

More information

Clostridium difficile Infection (CDI)

Clostridium difficile Infection (CDI) 18.09.10 월요집담회 Clostridium difficile Infection (CDI) R4 송주혜 Clostridium difficile infection (CDI) Anaerobic gram (+), spore-forming, toxin(tcda&tcdb)-producing bacillus Transmitted among humans through

More information

GUIDELINE FOR THE MANAGEMENT OF ANTIBIOTIC- ASSOCIATED DIARRHOEA IN ADULTS

GUIDELINE FOR THE MANAGEMENT OF ANTIBIOTIC- ASSOCIATED DIARRHOEA IN ADULTS GUIDELINE FOR THE MANAGEMENT OF ANTIBIOTIC- ASSOCIATED DIARRHOEA IN ADULTS Version 3.0 Date ratified May 2008 Review date May 2010 Ratified by NUH Antibiotic Guidelines Committee NUH Drugs and Therapeutics

More information

Duodenal infusion of donor feces for recurrent Clostridium difficile infection A French experience

Duodenal infusion of donor feces for recurrent Clostridium difficile infection A French experience Duodenal infusion of donor feces for recurrent Clostridium difficile infection A French experience Benoit Guery Unité des Maladies Infectieuses CHRU - Faculté de Médecine Lille Conflicts of interest Conferences,

More information

Journey to Decreasing Clostridium Difficile and the Unexpected Twist. Jackie Morton, Infection Prevention Cortney Swiggart, Medication Safety Officer

Journey to Decreasing Clostridium Difficile and the Unexpected Twist. Jackie Morton, Infection Prevention Cortney Swiggart, Medication Safety Officer Journey to Decreasing Clostridium Difficile and the Unexpected Twist Jackie Morton, Infection Prevention Cortney Swiggart, Medication Safety Officer 4/13/2018 Objectives Discuss the organism and clinical

More information

What s New for Clostridium difficile John Lynch MD MPH Harborview Medical Center University of Washington

What s New for Clostridium difficile John Lynch MD MPH Harborview Medical Center University of Washington What s New for Clostridium difficile 2013 John Lynch MD MPH Harborview Medical Center University of Washington Pathogenic Mechanisms of Diarrhea Toxins: Preformed: S aureus, C perfringens, B cereus Formed

More information

Managing Clostridium Difficile: An Old Bug With

Managing Clostridium Difficile: An Old Bug With 932 The Red Section see related editorial on page x Managing Clostridium Difficile: An Old Bug With New Tricks Stephen M. Vindigni, MD, MPH 1,2 and Christina M. Surawicz, MD 1 Am J Gastroenterol (2018)

More information

The incubation period is unknown. However; the onset of clinical disease is typically 5-10 days after initiation of antimicrobial treatment.

The incubation period is unknown. However; the onset of clinical disease is typically 5-10 days after initiation of antimicrobial treatment. C. DIFFICILE Case definition CONFIRMED CASE A patient is defined as a case if they are one year of age or older AND have one of the following requirements: A laboratory confirmation of a positive toxin

More information

HEALTHCARE- ASSOCIATED INFECTIONS: A FOCUS ON Clostridium difficile

HEALTHCARE- ASSOCIATED INFECTIONS: A FOCUS ON Clostridium difficile OBJECTIVES HEALTHCARE- ASSOCIATED INFECTIONS: A FOCUS ON Clostridium difficile Identify and describe the pathophysiology of C. diff. Identify and describe current therapies in treatment of C. diff Identify

More information

March 3, To: Hospitals, Long Term Care Facilities, and Local Health Departments

March 3, To: Hospitals, Long Term Care Facilities, and Local Health Departments March 3, 2010 To: Hospitals, Long Term Care Facilities, and Local Health Departments From: NYSDOH Bureau of Healthcare Associated Infections HEALTH ADVISORY: GUIDANCE FOR PREVENTION AND CONTROL OF HEALTHCARE

More information

Le infezioni da Clostridium difficile, gravi, ricorrenti e complicate Nicola Petrosillo

Le infezioni da Clostridium difficile, gravi, ricorrenti e complicate Nicola Petrosillo Le infezioni da Clostridium difficile, gravi, ricorrenti e complicate Nicola Petrosillo Istituto Nazionale per le Malattie Infettive «lazzaro Spallanzani», IRCCS-Roma The infectious cycle of transmission

More information

Literature Scan: Antibiotics for Clostridium difficile Infection. Month/Year of Review: May 2015 Date of Last Review: April 2012

Literature Scan: Antibiotics for Clostridium difficile Infection. Month/Year of Review: May 2015 Date of Last Review: April 2012 Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

CDI The Impact. Disclosures. Acknowledgments. Objectives and Agenda. What s in the Name? 11/14/2012. Lets Talk Numbers

CDI The Impact. Disclosures. Acknowledgments. Objectives and Agenda. What s in the Name? 11/14/2012. Lets Talk Numbers Disclosures No conflict of interest to declare Acknowledgments Objectives and Agenda Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA) Guidelines

More information

The Potential For Microbiome Modification In Critical Illness. Deborah Cook

The Potential For Microbiome Modification In Critical Illness. Deborah Cook The Potential For Microbiome Modification In Critical Illness Deborah Cook To review Objectives The microbiome & concepts about its modification during critical illness Interventions Predisposition to

More information

Clostridium Difficile Infection: Applying New Treatment Guidelines and Strategies to Reduce Recurrence Rate

Clostridium Difficile Infection: Applying New Treatment Guidelines and Strategies to Reduce Recurrence Rate Clostridium Difficile Infection: Applying New Treatment Guidelines and Strategies to Reduce Recurrence Rate Objectives Summarize the changing epidemiology and demographics of patients at risk for Clostridium

More information

A Pharmacist Perspective

A Pharmacist Perspective Leveraging Technology to Reduce CDI A Pharmacist Perspective Ed Eiland, Pharm.D., MBA, BCPS (AQ-ID) Clinical Practice and Business Supervisor Huntsville Hospital System Huntsville Hospital 881 licensed

More information

Probiotics: Their Role in Medicine Today. Objectives. Probiotics: What Are They? 11/3/2017

Probiotics: Their Role in Medicine Today. Objectives. Probiotics: What Are They? 11/3/2017 Probiotics: Their Role in Medicine Today Viki Barr Pharm.D., BCPS AQ ID Assistant Professor, Pharmacy Practice Rosalind Franklin University of Medicine and Science Clinical Pharmacist, Infectious Diseases

More information

GI Bacterial Infections (part-2)

GI Bacterial Infections (part-2) GI Bacterial Infections (part-2) Mohammed Abdulla Mehdi FIBMS (internal medicine), FIBMS (G&H) Clostridium difficile infection C. difficile is the most commonly diagnosed cause of antibioticassociated

More information

Learning Goals. Clostridium difficile. Historical Context. Historical Context 6/27/2012

Learning Goals. Clostridium difficile. Historical Context. Historical Context 6/27/2012 Learning Goals Clostridium difficile Justin L. Sewell, MD, MPH Assistant Clinical Professor of Medicine University of California San Francisco San Francisco General Hospital Understand the epidemiology,

More information

-2002: Rectal blood loss, UC? (no definite diagnosis) rectal mesalazine. -June 2008: Recurrence of rectal blood loss and urgency

-2002: Rectal blood loss, UC? (no definite diagnosis) rectal mesalazine. -June 2008: Recurrence of rectal blood loss and urgency SD, male 40 yrs. old. (680718M467.) -2002: Rectal blood loss, UC? (no definite diagnosis) rectal mesalazine -June 2008: Recurrence of rectal blood loss and urgency Total colonoscopy: ulcerative rectitis,

More information

... Inflammatory disorder of the colon that occurs as a complication of antibiotic treatment.

... Inflammatory disorder of the colon that occurs as a complication of antibiotic treatment. Definition Inflammatory disorder of the colon that occurs as a complication of antibiotic treatment. " Epidemiology Humans represent the main reservoir of Clostridium difficile, which is not part of the

More information

Management of Clostridium Difficile: Total Colectomy versus Colon Sparing Surgery

Management of Clostridium Difficile: Total Colectomy versus Colon Sparing Surgery Management of Clostridium Difficile: Total Colectomy versus Colon Sparing Surgery Rahul Narang, MD Colon and Rectal Surgery Assistant Professor of Surgery No Disclosure Clostridium Difficile Colitis: Treatments,

More information

Sherwood L. Gorbach, MD Professor of Public Health, Medicine, and Microbiology Tufts University School of Medicine

Sherwood L. Gorbach, MD Professor of Public Health, Medicine, and Microbiology Tufts University School of Medicine Sherwood L. Gorbach, MD Professor of Public Health, Medicine, and Microbiology Tufts University School of Medicine Chief Scientific Officer, Optimer Pharmaceuticals, Inc. Conflicts: Chief Scientific Officer,

More information

JMSCR Vol 05 Issue 07 Page July 2017

JMSCR Vol 05 Issue 07 Page July 2017 www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i7.15 Rapid Diagnosis of Toxigenic Clostridium

More information

THE USE OF LACTOBACILLUS IN THE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION IN HOSPITALIZED ADULT PATIENTS

THE USE OF LACTOBACILLUS IN THE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION IN HOSPITALIZED ADULT PATIENTS Virginia Commonwealth University VCU Scholars Compass Theses and Dissertations Graduate School 2009 THE USE OF LACTOBACILLUS IN THE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION IN HOSPITALIZED ADULT PATIENTS

More information

Annex C: - CDI What s the diff? 4 th Annual Outbreak Management Workshop September 19, 2013 Naideen Bailey & Grace Volkening

Annex C: - CDI What s the diff? 4 th Annual Outbreak Management Workshop September 19, 2013 Naideen Bailey & Grace Volkening Annex C: - CDI What s the diff? 4 th Annual Outbreak Management Workshop September 19, 2013 Naideen Bailey & Grace Volkening There s an updated Annex C Annex C is an extension to the PIDAC Infection Prevention

More information

Clostridium difficile infection (CDI) Week 52 (Ending 30/12/2017)

Clostridium difficile infection (CDI) Week 52 (Ending 30/12/2017) Clostridium difficile infection (CDI) Week 52 (Ending 30/12/2017) What is Clostridium difficile? Clostridium difficile is a Gram-positive anaerobic spore forming bacillus. It is ubiquitous in nature and

More information

CLOSTRIDIUM DIFFICILE: IMPROVING DIAGNOSIS AND TREATMENT. Joshua T. Watson, M.D. Lowcountry Gastroenterology Associates

CLOSTRIDIUM DIFFICILE: IMPROVING DIAGNOSIS AND TREATMENT. Joshua T. Watson, M.D. Lowcountry Gastroenterology Associates CLOSTRIDIUM DIFFICILE: IMPROVING DIAGNOSIS AND TREATMENT Joshua T. Watson, M.D. Lowcountry Gastroenterology Associates Learning Objectives Recognize patients who are highest risk for C. diff infections

More information

! Macrolide antibacterial. Fidaxomicin (Dificid ) package labeling. Optimer Pharmaceuticals, Inc. May 2011.

! Macrolide antibacterial. Fidaxomicin (Dificid ) package labeling. Optimer Pharmaceuticals, Inc. May 2011. Disclosure! I have no conflicts of interest related to this presentation Nina Naeger Murphy, Pharm.D., BCPS Clinical Pharmacy Specialist Infectious Diseases MetroHealth Medical Center Learning Objectives!

More information

Terapia dell infezione da Clostridium difficile. Massimo Coen I Div Mal Inf AO L Sacco

Terapia dell infezione da Clostridium difficile. Massimo Coen I Div Mal Inf AO L Sacco Terapia dell infezione da Clostridium difficile Massimo Coen I Div Mal Inf AO L Sacco Disease Severity Mild CDI 3 5 BM/day WBC 15,000/mm 3 Defining CDI Disease Severity Mild abdominal pain due to CDI Moderate

More information

Nicola Petrosillo Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani, IRCCS Roma. L infezione da C difficile grave o complicata

Nicola Petrosillo Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani, IRCCS Roma. L infezione da C difficile grave o complicata Nicola Petrosillo Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani, IRCCS Roma L infezione da C difficile grave o complicata Bagdasarian N et al. JAMA 2015; 313: 398-408 European Society

More information

more intense treatments are needed to get rid of the infection.

more intense treatments are needed to get rid of the infection. What Is Clostridium Difficile (C. Diff)? Clostridium difficile, or C. diff for short, is an infection from a bacterium that can grow in your intestines and cause bad GI symptoms. The main risk of getting

More information

Modern approach to Clostridium Difficile Infection

Modern approach to Clostridium Difficile Infection Modern approach to Clostridium Difficile Infection Pseudomembranous Colitis: Principles for diagnosis and treatment Aggelos Stefos Internist, Infectious diseases Specialist Department of Medicine and Research

More information

Updates to pharmacological management in the prevention of recurrent Clostridium difficile

Updates to pharmacological management in the prevention of recurrent Clostridium difficile Updates to pharmacological management in the prevention of recurrent Clostridium difficile Julia Shlensky, PharmD PGY2 Internal Medicine Resident September 12, 2017 2017 MFMER slide-1 Clinical Impact Increasing

More information

Antibiotic Associated Diarrhea (AAD) and Clostridium Difficile Infection (CDI)

Antibiotic Associated Diarrhea (AAD) and Clostridium Difficile Infection (CDI) Antibiotic Associated Diarrhea (AAD) and Clostridium Difficile Infection (CDI) Dario Conte, M.D. Gastroenterology and Endoscopy Unit Postgraduate School of Gastroenterology Fondazione IRCCS Ca Granda Ospedale

More information

Patient presentation

Patient presentation Update: Clostridium difficile Colitis David H. Kerman, MD Assistant Professor of Clinical Medicine Director, Fellowship Program Division of Gastroenterology University of Miami Miller School of Medicine

More information

DETECTION OF TOXIGENIC CLOSTRIDIUM DIFFICILE

DETECTION OF TOXIGENIC CLOSTRIDIUM DIFFICILE CLINICAL GUIDELINES For use with the UnitedHealthcare Laboratory Benefit Management Program, administered by BeaconLBS DETECTION OF TOXIGENIC CLOSTRIDIUM DIFFICILE Policy Number: PDS 021 Effective Date:

More information

Nursing Infectious Diseases Topics. David H. Spach, MD Professor of Medicine Division of Infectious Diseases University of Washington, Seattle

Nursing Infectious Diseases Topics. David H. Spach, MD Professor of Medicine Division of Infectious Diseases University of Washington, Seattle Nursing Infectious Diseases Topics David H. Spach, MD Professor of Medicine Division of Infectious Diseases University of Washington, Seattle Clostridium difficile Free Access Via Web Source: Cohen SH,

More information

C.Difficile Associated Diarrhea Overview & Management. Sajal Chopra Pharm D. Candidate

C.Difficile Associated Diarrhea Overview & Management. Sajal Chopra Pharm D. Candidate C.Difficile Associated Diarrhea Overview & Management Sajal Chopra Pharm D. Candidate Learning Objectives 1. Recognize the increasing incidence of C.difficile associated diarrhea (CDAD) and its risk factors

More information

Clostridium difficile Infection (CDI) Guideline Update:

Clostridium difficile Infection (CDI) Guideline Update: Clostridium difficile Infection (CDI) Guideline Update: Understanding the Data Behind the Recommendations Erik R. Dubberke, MD, MSPH A Webinar for HealthTrust Members Professor of Medicine September 24,

More information

Long-Term Care Updates

Long-Term Care Updates Long-Term Care Updates April 2018 By Austin Smith, PharmD Candidate and Lindsay Slowiczek, PharmD is the most common healthcare-acquired infection (HAI) in the United States. 1,2 A 2014 prevalence survey

More information

Clostridium Difficile colitismore

Clostridium Difficile colitismore Clostridium Difficile colitismore virulent than ever ECHO- February 18, 2016 Charles Krasner, M.D. UNR School of Medicine Sierra NV Veterans Affairs Hospital Growing problem of pseudomembranous colitis

More information

Fecal Microbiota Transplantation (FMT): Current Concepts in Clostridium difficile and beyond

Fecal Microbiota Transplantation (FMT): Current Concepts in Clostridium difficile and beyond Fecal Microbiota Transplantation (FMT): Current Concepts in Clostridium difficile and beyond Amir Patel, MD Assistant Professor of Medicine Froedtert Hospital and the Medical College of Wisconsin I have

More information

Fecal transplantation as a treatment option for recurrent Clostridium difficile infection

Fecal transplantation as a treatment option for recurrent Clostridium difficile infection Fecal transplantation as a treatment option for recurrent Clostridium difficile infection Josbert Keller Department of Gastroenterology Haga Teaching Hospital, The Hague Case: 81 yrs, CVA, recurrent UTI,

More information

Inter-hospital Geriatrics Meeting August 2014 The Watery Curse

Inter-hospital Geriatrics Meeting August 2014 The Watery Curse Inter-hospital Geriatrics Meeting August 2014 The Watery Curse Speaker: Dr. KK Yam (QMH) Supervisor: Dr. Patrick Chiu Patient s history F/95 Lives with daughter & maid ADL partially dependent. Walks with

More information

International Journal of Food and Allied Sciences

International Journal of Food and Allied Sciences International Journal of Food and Allied Sciences ISSN: 2415-0290 (Print) ISSN: 2413-2543 (Online) DOI:10.21620/ijfaas.2017120-26 Research Article History The Role of Saccharomyces boulardii in the Treatment

More information

Disclosure. Objectives. Assessment Questions. History. Clinical Case 2/27/2015. Clostridium difficile update and new therapies

Disclosure. Objectives. Assessment Questions. History. Clinical Case 2/27/2015. Clostridium difficile update and new therapies Disclosure Clostridium difficile update and new therapies Corey Frederick, PharmD PGY-2 Pharmacy Resident, Infectious Diseases Jackson Memorial Hospital Miami, Florida I do not have a vested interest in

More information

Clostridium difficile Not Just a Hospital Problem Anymore. Objectives. The C. difficile Carrier State. Conflicts of Interest Disclosure

Clostridium difficile Not Just a Hospital Problem Anymore. Objectives. The C. difficile Carrier State. Conflicts of Interest Disclosure Conflicts of Interest Disclosure Daniel Leffler, MD, MS I disclose the following financial relationships with commercial entities that produce health carerelated products or services relevant to the content

More information

Los Angeles County Department of Public Health: Your Partner in CDI Prevention

Los Angeles County Department of Public Health: Your Partner in CDI Prevention Los Angeles County Department of Public Health: Your Partner in CDI Prevention Dawn Terashita, MD, MPH Acute Communicable Disease Control Los Angeles County Department of Public Health dterashita@ph.lacounty.gov

More information

declara&ons Clostridium difficile infec&on. Time to wake up and smell the..., um, nevermind. OK, next slide please. Bruce Dalton, BScPhm. PharmD.

declara&ons Clostridium difficile infec&on. Time to wake up and smell the..., um, nevermind. OK, next slide please. Bruce Dalton, BScPhm. PharmD. Clostridium difficile infec&on. Time to wake up and smell the..., um, nevermind. OK, next slide please. Bruce Dalton, BScPhm. PharmD. declara&ons No financial disclosures Personal acquaintance, co- worker,

More information

Clostridium difficile infections: Drug treatment re-evaluated

Clostridium difficile infections: Drug treatment re-evaluated Clostridium difficile infections: Drug treatment re-evaluated Kimberly D. Leuthner, PharmD University Medical Center of Southern Nevada August 11, 2016 Random Fact: The human body has 10 13 human cells

More information

Understanding C. diff. atomalliance.org/cdifftraining

Understanding C. diff. atomalliance.org/cdifftraining Understanding C. diff atomalliance.org/cdifftraining This booklet is a printed guide of the online educational resource atomalliance.org/cdifftraining Target Audience Understanding C. diff This educational

More information

12/14/2009. Diagnostic considerations: C. difficile in IBD

12/14/2009. Diagnostic considerations: C. difficile in IBD Diagnosis and treatment of Gastrointestinal Tract Infections in IBD Case Studies Leonard Baidoo,MD David Binion,MD University of Pittsburgh Medical Center Pittsburgh, Pennsylvania Case 1 46yr old man,1

More information

8/29/2016 DIVERTICULAR DISEASE: WHAT EVERY NURSE PRACTITIONER SHOULD KNOW. LENORE LAMANNA Ed.D, ANP-C LEARNING OBJECTIVES

8/29/2016 DIVERTICULAR DISEASE: WHAT EVERY NURSE PRACTITIONER SHOULD KNOW. LENORE LAMANNA Ed.D, ANP-C LEARNING OBJECTIVES DIVERTICULAR DISEASE: WHAT EVERY NURSE PRACTITIONER SHOULD KNOW LENORE LAMANNA Ed.D, ANP-C LEARNING OBJECTIVES Define Diverticular Disease Discuss Epidemiology and Pathophysiology of Diverticular disease

More information

SMT19969: A Selective Therapy for C. difficile Infection

SMT19969: A Selective Therapy for C. difficile Infection SMT19969: A Selective Therapy for C. difficile Infection One Bug, One Drug 25 th September 2012 SMT19969: A Selective Therapy for CDI SMT19969 is a novel antibiotic for the specific treatment of Clostridium

More information

ADJUVANT TIGECYCLINE FOR SEVERE CLOSTRIDIUM DIFFICILE-ASSOCIATED DIARRHEA

ADJUVANT TIGECYCLINE FOR SEVERE CLOSTRIDIUM DIFFICILE-ASSOCIATED DIARRHEA ADJUVANT TIGECYCLINE FOR SEVERE CLOSTRIDIUM DIFFICILE-ASSOCIATED DIARRHEA Candace Marr, DO Catholic Health System University at Buffalo, NY Kevin Shiley, MD Catholic Health System Buffalo, NY FINANCIAL

More information

CHRONIC DIARRHEA DR. PHILIP K. BLUSTEIN M.D. F.R.C.P.(C) DEFINITION: *LOOSE, WATERY STOOLS *MORE THAN 3 TIMES A DAY *FOR MORE THAN 4 WEEKS

CHRONIC DIARRHEA DR. PHILIP K. BLUSTEIN M.D. F.R.C.P.(C) DEFINITION: *LOOSE, WATERY STOOLS *MORE THAN 3 TIMES A DAY *FOR MORE THAN 4 WEEKS DR. PHILIP K. BLUSTEIN M.D. F.R.C.P.(C) 415 14 TH ST. NW. CALGARY AB T2N2A1 PHONE (403) 270-9555 FAX (403) 270-7479 CHRONIC DIARRHEA DEFINITION: *LOOSE, WATERY STOOLS *MORE THAN 3 TIMES A DAY *FOR MORE

More information

Clostridium difficile: An Overview

Clostridium difficile: An Overview Clostridium difficile: An Overview CDI Webinar July 11, 2017 PUBLIC HEALTH DIVISION Acute and Communicable Disease Prevention Section Outline Background Microbiology Burden Pathogenesis Diagnostic testing

More information

Treating and Preventing. C. difficile Infections A Review of the Research for Adults

Treating and Preventing. C. difficile Infections A Review of the Research for Adults Treating and Preventing C. difficile Infections A Review of the Research for Adults e Is This Information Right for Me? This information is right for you if: Your health care professional has said that

More information

C. difficile: The Changing Epidemiology Evaluations Clostridium difficile Thank You to our Sponsors

C. difficile: The Changing Epidemiology Evaluations Clostridium difficile Thank You to our Sponsors C. difficile: The Changing Epidemiology Ghinwa Dumyati, MD University of Rochester Monroe County Department of Public Health Thank You to our Sponsors Evaluations School of Public Health, University at

More information

Clostridium difficile Infection (CDI) Guideline

Clostridium difficile Infection (CDI) Guideline Clostridium difficile Infection (CDI) Guideline Site Applicability All VCH PHC acute care and residential sites. Practice Level Physicians basic skill Pharmacists basic skill Nurses (RN, LPN, RPN) basic

More information

PROBIONA. PROBIOTICS with 5 bacterial strains. Suitable during and after the use of antibiotics to restore intestinal microflora.

PROBIONA. PROBIOTICS with 5 bacterial strains. Suitable during and after the use of antibiotics to restore intestinal microflora. PROBIONA Probiotic supplement for adults PROBIOTICS with 5 bacterial strains Suitable during and after the use of antibiotics to restore intestinal microflora. 2.850 billion cfu per capsule guaranteed

More information

Spectrum of Diverticular Disease. Outline

Spectrum of Diverticular Disease. Outline Spectrum of Disease ACG Postgraduate Course January 24, 2015 Lisa Strate, MD, MPH Associate Professor of Medicine University of Washington, Seattle, WA Outline Traditional theories and updated perspectives

More information

Corporate Medical Policy Fecal Microbiota Transplantation

Corporate Medical Policy Fecal Microbiota Transplantation Corporate Medical Policy Fecal Microbiota Transplantation File Name: Origination: Last CAP Review: Next CAP Review: Last Review: Fecal_microbiota_transplantation 7/2014 11/2017 11/2018 11/2017 Description

More information

Responders as percent of overall members in each category: Region: New England 50 (57% of 87 members) 46 (57% of 81 members) 21 (55% of 38 members)

Responders as percent of overall members in each category: Region: New England 50 (57% of 87 members) 46 (57% of 81 members) 21 (55% of 38 members) Infectious Diseases Society of America Emerging Infections Network Report for Query: Recurrent C. difficile Infections (CDI) Overall response rate: 621/1212 (51.2%) physicians responded from 09/26/12 to

More information

500,000 29,000. New 2015 Data. Lessa et al, N Eng J Med 2015: 34.2% of CDI cases were considered community-acquired

500,000 29,000. New 2015 Data. Lessa et al, N Eng J Med 2015: 34.2% of CDI cases were considered community-acquired Cost-effective Treatment of Clostridium difficile Infection in the ICU Kevin W. Garey, PharmD, MS. Professor and Chair University of Houston College of Pharmacy New 2015 Data 500,000 29,000 Lessa et al,

More information

The epidemiology of Clostridium difficile infection (CDI) in hospitals, longterm care and the community. J Scott Weese DVM DVSc DipACVIM

The epidemiology of Clostridium difficile infection (CDI) in hospitals, longterm care and the community. J Scott Weese DVM DVSc DipACVIM The epidemiology of Clostridium difficile infection (CDI) in hospitals, longterm care and the community J Scott Weese DVM DVSc DipACVIM C. difficile Gram positive anaerobic sporeforming bacterium first

More information

Study on Incidence of Antibiotic Associated Diarrhoea in General Paediatric Ward

Study on Incidence of Antibiotic Associated Diarrhoea in General Paediatric Ward HK J Paediatr (new series) 2002;7:33-38 Study on Incidence of Antibiotic Associated Diarrhoea in General Paediatric Ward CM HUI, K TSE Abstract Objective: To estimate the incidence rate and risk factors

More information

Enteric Illness. Shigellosis

Enteric Illness. Shigellosis Section 3 Page 1 of 7 Notification Timeline: From Lab/Practitioner to Public Health: Immediately. From Public Health to Saskatchewan Health: Within 72 hours. Public Health Follow-up Timeline: Initiate

More information

New approaches to treating

New approaches to treating 9:45 10:45am New Approaches to Treating C Difficile Infection SPEAKER Kalpana Gupta, MD, MPH Presenter Disclosure Information The following relationships exist related to this presentation: Kalpana Gupta,

More information

Long-Term Care Updates

Long-Term Care Updates Long-Term Care Updates April 2017 Bezlotoxumab to Prevent Recurrent Infection By Amy Wilson, PharmD and Zara Risoldi Cochrane, PharmD, MS, FASCP Introduction The Gram-positive bacteria is a common cause

More information

New approaches to treating Clostridium difficile Infection

New approaches to treating Clostridium difficile Infection 7:45 8:45 am New Approaches to Treating C. difficile Infection SPEAKER Fred A. Lopez, MD, MACP Presenter Disclosure Information The following relationships exist related to this presentation: Fred A. Lopez,

More information